💊 الأدوية من أ إلى ي 🧬 الأهداف 🛠 الأدوات 📚 الأدلة
جميع الأدوية تصنيفات الأدوية المجالات العلاجية الآثار الجانبية
الأدلة المسرد الجدول الزمني
المقارنات مسارات الأدوية عائلات الأدوية
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Raltegravir Potassium

CHEMBL518520 Phase 4 معتمد Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
482.5 g/mol
LogP
—
Phase
4

The potassium salt formulation of raltegravir used in combination with other antiretroviral drugs to suppress HIV replication and maintain immune function. It is well-tolerated and has a favorable drug interaction profile compared to some older HIV medications.

الوزن الجزيئي

482,5000 g/mol

TPSA

153,00 Ų

المجالات العلاجية

Osteoporosis Generalized Anxiety Disorder Multiple Sclerosis Non-Alcoholic Fatty Liver Disease Hyperlipidemia Lymphoma HIV/AIDS Hepatitis C Tuberculosis Cardiovascular Disease Leukemia

آلية العمل

Inhibits viral integrase, preventing the insertion of viral DNA into the host cell genome and blocking viral replication.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

الآلية

Inhibits viral integrase, preventing the insertion of viral DNA into the host cell genome and blocking viral replication.

البنية ثنائية الأبعاد

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
Cc1nnc(C(=O)NC(C)(C)c2nc(C(=O)NCc3ccc(F)cc3)c([O-])c(=O)n2C)o1.[K+]

                

                

                
                

                    
InChI

                    
InChI=1S/C20H21FN6O5.K/c1-10-25-26-17(32-10)16(30)24-20(2,3)19-23-13(14(28)18(31)27(19)4)15(29)22-9-11-5-7-12(21)8-6-11;/h5-8,28H,9H2,1-4H3,(H,22,29)(H,24,30);/q;+1/p-1

                

                

                

                    
                    

                        
Molecular Formula

                        
C20H20FKN6O5

                    

                    
                    

                        
HBD / HBA

                        
2 / 9

                    

                    
                    

                        
الروابط القابلة للدوران

                        
6

                    

                    
                    
                    

                        
الذرات الثقيلة

                        
33

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
الأسئلة الشائعة

                

                    
                    

                        
                        

                            
The potassium salt formulation of raltegravir used in combination with other antiretroviral drugs to suppress HIV replication and maintain immune function. It is well-tolerated and has a favorable drug interaction profile compared to some older HIV medications.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Inhibits viral integrase, preventing the insertion of viral DNA into the host cell genome and blocking viral replication.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Raltegravir Potassium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL518520.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 23668479.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
إخلاء المسؤولية الطبية

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.